Cracking the Brain’s Code: Aerska’s $39M Leap

Aerska lands $39M to deliver RNA into the brain, signaling biotech’s next big frontier

23 Feb 2026

The race to outsmart one of biology’s toughest defenses is heating up. Irish biotech Aerska has pulled in $39 million to advance a delivery platform designed to carry RNA medicines straight into the brain, a step that could reshape how neurological diseases are treated.

The funding round was co-led by EQT Life Sciences, through its LSP Dementia Fund, and venture firm age1, with Iaso Ventures also joining in. The raise brings Aerska’s total funding to about $60 million since launching in late 2025. That rapid backing reflects a growing belief among investors that the future of biotech may hinge less on discovering new drugs and more on getting them where they need to go.

For decades, the blood brain barrier has been both protector and problem. It shields the brain from harmful substances, yet it also blocks many promising therapies. Scientists have struggled to slip medicines past this defense without resorting to invasive techniques.

Aerska’s pitch is straightforward but ambitious. The company aims to move RNA-based treatments across the barrier using standard injections, avoiding surgical procedures. If the platform works as intended, it could open the door to more practical treatments for Alzheimer’s and other serious neurological disorders.

The broader bet is that delivery platforms, not just breakthrough molecules, will define the next era of genetic medicine. RNA therapies have already changed care in parts of the body such as the liver. The central nervous system, however, remains one of the industry’s biggest untapped markets and one of its most complex.

The deal also reflects a shift in how biotech is funded. Investors are favoring scalable platforms that can support multiple drug programs over single-asset plays. A flexible system that can be applied across diseases offers more shots on goal and a clearer path to partnerships with larger pharmaceutical companies.

Big hurdles remain. Aerska must prove its technology is safe, precise, and durable in human trials, and regulators will scrutinize potential off-target effects.

Still, momentum is building. If Aerska can crack the code, the effort to unlock the brain could move from distant promise to tangible progress.